Key Events This Week
29 Jun: Surge in call option activity ahead of June expiry
30 Jun: Significant open interest increase amid bullish positioning
1 Jul: Continued open interest surge with positive price momentum
3 Jul: New 52-week high at Rs 1919.7 and mixed options activity
29 June: Call Option Activity Signals Bullish Sentiment Ahead of June Expiry
Sun Pharmaceutical’s shares opened the week at Rs.1,872.60 and closed slightly lower at Rs.1,862.70 (-0.53%), yet the day was marked by a notable surge in call option trading. The ₹1,900 strike call options expiring on 30 June saw 7,480 contracts traded, with open interest at 4,665 contracts, indicating strong bullish positioning ahead of expiry.
The stock traded near its 52-week high of Rs.1,916.60, supported by technical strength as it remained above all major moving averages. Despite a slight dip in delivery volumes, the underlying price resilience and active derivatives market suggested investor confidence in a potential breakout.
30 June: Open Interest Surges Amid Growing Market Participation
On 30 June, the stock closed at Rs.1,865.95, gaining 0.17%, outperforming the Sensex which declined marginally by 0.01%. Open interest in derivatives rose sharply by 14.3% to 1,30,326 contracts, with a daily volume of 1,10,207 contracts, reflecting fresh positioning rather than unwinding.
This increase in open interest, combined with the stock’s proximity to its 52-week high, underscored sustained bullish sentiment. The futures and options notional values were substantial, highlighting active institutional and retail participation. However, delivery volumes showed a decline, suggesting a shift towards leveraged derivatives exposure.
1 July: Continued Open Interest Growth and Positive Price Momentum
Sun Pharma’s price rose modestly by 0.30% to Rs.1,871.55 on 1 July, keeping pace with the Sensex’s 0.45% gain. Open interest further increased by 12.47% to 81,662 contracts, with volume of 38,656 contracts, signalling ongoing fresh bets on the stock’s direction.
The stock outperformed its sector by 0.84%, supported by a mojo grade upgrade to Buy and a mojo score of 74.0. Delivery volumes improved, rising 8.28% over the five-day average, indicating renewed investor participation in the cash market alongside derivatives activity.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
3 July: New 52-Week High Amid Mixed Options Activity
Sun Pharmaceutical Industries Ltd reached a new 52-week high of Rs.1,919.70 on 3 July, closing at Rs.1,904.65 (+1.77%), outperforming the Sensex’s 0.15% gain. The stock’s three-day rally delivered a cumulative return of 2.86%, supported by strong technical indicators and sector-wide strength as NIFTY PHARMA and S&P Bse Healthcare indices also hit new highs.
Despite the bullish price action, derivatives activity showed complexity. Call options at the ₹1,900 strike expiring on 28 July saw 4,102 contracts traded, signalling continued optimism. Simultaneously, put options at the same strike witnessed 4,257 contracts traded, indicating hedging or cautious positioning amid the strong rally.
The stock’s mojo grade remained Buy with a mojo score of 74.0, reflecting robust fundamentals including a net-debt-free balance sheet, steady sales growth, and institutional investor confidence with a 37.04% stake. However, recent quarterly profit trends showed a slight decline, warranting attention to earnings momentum.
Thinking about Sun Pharmaceutical Industries Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this large-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Daily Price Comparison: Sun Pharmaceutical vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-29 | Rs.1,872.60 | – | 35,960.98 | – |
| 2026-06-30 | Rs.1,862.70 | -0.53% | 35,958.71 | -0.01% |
| 2026-07-01 | Rs.1,865.95 | +0.17% | 36,119.01 | +0.45% |
| 2026-07-02 | Rs.1,871.55 | +0.30% | 36,376.02 | +0.71% |
| 2026-07-03 | Rs.1,904.65 | +1.77% | 36,431.45 | +0.15% |
Key Takeaways
Positive Signals: Sun Pharmaceutical demonstrated consistent price gains over the week, outperforming the Sensex by 0.40%. The stock’s new 52-week high and sustained trading above all major moving averages confirm strong technical momentum. The mojo grade upgrade to Buy and a mojo score of 74.0 reflect improving fundamentals and investor confidence. Active call option volumes and rising open interest indicate bullish market positioning and anticipation of further upside.
Cautionary Notes: Despite price strength, delivery volumes showed some decline midweek, suggesting a shift towards derivatives rather than outright stock accumulation. The simultaneous surge in put option activity at the ₹1,900 strike on 3 July signals hedging or cautious sentiment amid the rally. Recent quarterly profit declines and a premium valuation (P/B of 5.4 and PEG of 4) warrant monitoring of earnings momentum and valuation sustainability.
Conclusion
Sun Pharmaceutical Industries Ltd’s performance in the week ending 3 July 2026 was characterised by steady gains, strong technical positioning, and active derivatives market engagement. The stock’s new 52-week high and mojo grade upgrade underpin a positive medium-term outlook, supported by robust fundamentals and institutional backing. However, the mixed signals from put option activity and recent profit trends suggest investors should remain vigilant to potential volatility and valuation pressures. Overall, Sun Pharma remains a key large-cap stock within the Pharmaceuticals & Biotechnology sector, demonstrating resilience and growth potential amid evolving market dynamics.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
